Concepedia

Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?

Renaud Sabatier, J.C. Eymard, Jochen Walz, Jean‐Laurent Deville, H Narbonne, Jean‐Marie Boher, Naji Salem, M. Marcy, Serge Brunelle, Patrice Viens,

Annals of Oncology · 2011 · 69 citations · 26 references

DOIFull text

Open access

Concepts

References

26

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text

, , +14

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett et al. · The Lancet · 2006 · 2.6K citations

, , +8

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · Journal of Clinical Oncology · 2009 · 2.2K citations

, , +13

Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma

Robert J. Motzer, Madhu Mazumdar, Jennifer Bacik et al. · Journal of Clinical Oncology · 1999 · 1.8K citations

, , +17

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text

, , +17